Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Histamine
Drug ID BADD_D01071
Description A depressor amine derived by enzymatic decarboxylation of histidine. It is a powerful stimulant of gastric secretion, a constrictor of bronchial smooth muscle, a vasodilator, and also a centrally acting neurotransmitter.
Indications and Usage Histamine phosphate is indicated as a diagnostic aid for the evaluation of gastric acid secretory function.
Marketing Status approved; investigational
ATC Code L03AX14
DrugBank ID DB05381
KEGG ID D08040
MeSH ID D006632
PubChem ID 774
TTD Drug ID D04USC
NDC Product Code 65044-9998; 63083-1522; 81701-111
UNII 820484N8I3
Synonyms Histamine | Peremin | Histamine Dihydrochloride | Histamine Hydrochloride | Ceplene
Chemical Information
Molecular Formula C5H9N3
CAS Registry Number 51-45-6
SMILES C1=C(NC=N1)CCN
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Menopausal symptoms21.02.02.002--Not Available
Myalgia15.05.02.001--
Nasal congestion22.04.04.001--
Nausea07.01.07.001--
Neoplasm16.16.02.001--Not Available
Nervous system disorder17.02.10.001--Not Available
Neutropenia01.02.03.004--Not Available
Night sweats23.02.03.006; 08.01.03.031--Not Available
Oedema peripheral14.05.06.011; 08.01.07.007; 02.05.04.007--
Pain08.01.08.004--
Pain in extremity15.03.04.010--
Palpitations02.11.04.012--
Paraesthesia23.03.03.094; 17.02.06.005--
Pneumonia22.07.01.003; 11.01.09.003--Not Available
Pruritus23.03.12.001--
Rash23.03.13.0010.000637%Not Available
Shock24.06.02.002--Not Available
Skin disorder23.03.03.007--Not Available
Stomatitis07.05.06.005--
Tachycardia02.03.02.007--Not Available
Thrombocytopenia01.08.01.002--Not Available
Upper respiratory tract infection22.07.03.011; 11.01.13.009--
Urticaria23.04.02.001; 10.01.06.001--
Vertigo17.02.12.002; 04.04.01.003--
Vomiting07.01.07.003--
Weight decreased13.15.01.005--
Wheezing22.03.01.009--
Lymphatic disorder01.09.01.003--Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Injection site swelling12.07.03.018; 08.02.03.017--Not Available
The 3th Page    First    Pre   3 4    Next   Last    Total 4 Pages